APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

November 4, 2026

The Secretary,
Bombay Stock Exchange Ltd
(BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code – 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051.
Scrip Code– APOLLOHOSP
ISIN INE437A01024

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

We refer to our letters dated 24 September 2026 and 12 October 2026 regarding the captioned subject.

The Board of Directors of the Company, at its meeting held today, inter alia, considered and approved/took note of the following matters:

1. Unaudited Financial Results

The Board approved the unaudited standalone and consolidated financial results of the Company for the three and six months ended 30 September 2026.

The said financial results, which have been subjected to limited review by the Statutory Auditors of the Company, together with the Limited Review Reports thereon, are enclosed as Annexure A**.**

The unaudited financial results will be published in the newspapers in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospi
Website : www.apollohospitals.com

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

The financial results and the Limited Review Reports will also be made available on the Company's website at www.apollohospitals.com.

2. Changes in Senior Management Personnel

In terms of Regulation 30 of the SEBI Listing Regulations, read with the applicable SEBI Master Circular, as amended from time to time, we wish to inform you that Dr. Madhu Sasidhar, a designated Senior Managerial Personnel (SMP) of the Company, will cease to hold the position of President & CEO – Hospitals Division, effective from the closure of business hours on November 14, 2026 consequent to the successful completion of his employment tenure.

There is no material reason for the cessation of his office other than the reason stated above.

During his tenure with the Company, Dr. Madhu Sasidhar made significant contributions towards strengthening clinical excellence practices and in augmenting the Company's digital health capabilities.

Leadership Talent Addition

In line with the Company's leadership strengthening initiatives and to ensure seamless business continuity, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors designated the following personnel as Senior Management Personnel of the Company:

Dr. Ritu Garg, Chief Executive Officer, Multi Regions (North, Central, Western and Eastern Regions). She has over two decades of healthcare experience, she brings extensive expertise in operations, growth, transformation and innovation. A clinician by training, she holds an MBBS, MS and an MBA in Finance & Strategy.

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospi
Website : www.apollohospitals.com

Mr. Anand Wasker, Chief Business Officer- International. He has over 26 years of leadership experience building, scaling and transforming large service businesses across healthcare, financial services, telecom, education, beauty and wellness consumer services. He holds a Master's degree in Business Management.

Dr. N. Venkatesan, Chief Procurement Officer. He has over 25 years of diverse experience across healthcare procurement, supply chain, pharmacy operations, materials management, commercial functions and hospital project execution. He holds a Ph.D. in Hospital Supply Chain Management and an MBA in Systems.

The support functions & other regions previously reporting to the President & CEO will report to the Project Management Office under the guidance of the Managing Director.

The requisite disclosures in relation to the above, as required under the SEBI Listing Regulations and applicable SEBI circulars, are enclosed as follows:

Annexure B – Cessation of Dr. Madhu Sasidhar as President & CEO – Hospitals Division and SMP of the Company; and

Annexure C – Details of designation of Senior Management Personnel.

3. Completion of Divestment by Apollo Health and Lifestyle Limited in Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited as well as receipt of consideration and allotment of securities representing an effective 9.9% equity stake in Kids Clinic India Limited

The Company had earlier informed the Stock Exchanges that, at its meeting held on 20 May 2026, the Board had approved the divestment by Apollo Health and Lifestyle Limited ("AHLL"), a wholly owned subsidiary of the Company, of its entire shareholding in Apollo Specialty Hospitals Private Limited ("ASHPL") and Apollo Fertility Centre Private Limited ("AFCPL") to Kids Clinic India Limited ("KCIL"), which operates under the brand name "Cloudnine".

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospi
Website : www.apollohospitals.com

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

The transaction was envisaged at an enterprise value of approximately ₹15,500 million, comprising cash consideration of ₹7,650 million and an effective equity stake of approximately 9.9% in KCIL, valued at ₹7,850 million.

We wish to further inform you that transaction closure has been fully ensured on 3rd November 2026. AHLL has received the agreed consideration and has been allotted securities in KCIL representing an effective equity stake of approximately 9.9%.

Consequently, ASHPL and AFCPL have ceased to be subsidiaries of AHLL.

Kindly take the above information on record.

The Board Meeting commenced today at 3.20 p.m and concluded at 5.35 p.m.

The above information is also being made available on the Company's website at www.apollohospitals.com

Thanking you,

Yours faithfully
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
Sr. VICE PRESIDENT – FINANCE
AND COMPANY SECRETARY

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

SANKARAN ARAYANAN MUTHU KRISHNAN
Digitally signed by SANKARANARAYANAN MUTHU KRISHNAN
Date: 2026.11.04 17:40:32 +05'30'

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospi
Website : www.apollohospitals.com

Annexure – A

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com

Website: www.apollohospitals.com

Statement of Standalone unaudited Financial Results for the three months and six months ended September 30, 2026

(Rs. in Million)

Particulars	Three months ended 30/09/2026	Preceeding three months ended 30/06/2026	Corresponding three months ended 30/09/2025	Year to date figures for current period ended 30/09/2026	Year to date figures for previous period ended 30/09/2025	Previous year ended 31/03/2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
(a) Revenue from operations	29,029	26,561	23,561	55,590	45,240	93,262
(b) Other income	1,114	471	1,411	1,585	1,736	3,718
Total income (a + b)	**30,143**	**27,032**	**24,972**	**57,175**	**46,976**	**96,980**
2 Expenses						
(a) Cost of materials consumed	7,299	6,671	6,112	13,970	12,009	24,188
(b) Employee benefits expense	5,301	4,583	4,312	9,885	8,349	16,862
(c) Finance costs	712	683	579	1,395	1,167	2,417
(d) Depreciation and amortisation expenses	1,410	1,343	1,224	2,753	2,456	5,004
(e) Other expenses	9,203	8,745	7,208	17,947	13,492	28,932
Total expenses	**23,925**	**22,025**	**19,435**	**45,950**	**37,473**	**77,403**
3 Profit before tax and exceptional items (1) - (2)	**6,218**	**5,007**	**5,537**	**11,225**	**9,503**	**19,577**
4 Exceptional item (Refer note 7)	-	-		-	-	(114)
5 Profit before tax (3) + (4)	**6,218**	**5,007**	**5,537**	**11,225**	**9,503**	**19,463**
6 Tax expense						
Current tax	1,538	1,246	1,232	2,785	2,125	4,573
Deferred tax	(77)	(91)	106	(167)	110	(36)
7 Profit after tax for the period / year (5) - (6)	**4,757**	**3,852**	**4,199**	**8,607**	**7,268**	**14,926**
8 Other comprehensive income/(loss)						
Items that will not be reclassified to profit or loss						
(a) Remeasurement gains/(losses) on defined benefit plans	(116)	45	(108)	(71)	(32)	(142)
(b) Net change in fair value of investments in equity instruments measured at fair value	-	-	-	-		(10)
(c) Income tax relating to items that will not be reclassified to profit or loss	29	(11)	27	18	8	36
Total other comprehensive income/ (loss)	(87)	34	(81)	(53)	(24)	(116)
9 Total comprehensive income for the period/year (7) + (8)	**4,670**	**3,886**	**4,118**	**8,554**	**7,244**	**14,810**
10 Paid-up equity share capital (Face value Rs.5/- per share)				719	719	719
11 Reserves (excluding revaluation reserves)				1,06,381	92,430	98,913
12 Earnings per equity share ('EPS') of Rs.5/- each						
Basic EPS for the period/year (Rs.)	*33.08	*26.79	*29.20	*59.86	*50.55	103.81
Diluted EPS for the period/year (Rs.)	*33.06	*26.78	*29.20	*59.82	*50.55	103.74
13 Additional Information :-						
Earnings before finance costs, tax, depreciation and amortization, other income, exceptional items (EBITDA) (refer foot note)	7,226	6,562	5,929	13,788	11,390	23,280

*Not annualised

Foot note:

1 The Company has presented EBITDA additionally as part of standalone financial results.

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Annexure-I

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Standalone Balance Sheet

(Rs. in Million)

Particulars	As at 30-Sep-26	As at 31-Mar-26
	Unudited	Audited
ASSETS		
Non-current assets		
(a) Property, plant and equipment	56,448	54,452
(b) Right-of-use assets	13,693	13,767
(c) Capital work-in-progress	5,491	3,015
(d) Other intangible assets	745	945
(e) Intangible assets under development	228	182
(f) Financial assets		
(i) Investments	38,789	38,769
(ii) Loans	6,599	5,589
(iii) Other financial assets	1,511	1,730
(g) Income tax asset (net)	87	376
(h) Other non-current assets	1,793	1,816
Total non-current assets	**1,25,384**	**1,20,640**
Current assets		
(a) Inventories	1,726	1,468
(b) Financial assets		
(i) Investments	8,914	10,158
(ii) Trade receivables	10,493	8,473
(iii) Cash and cash equivalents	2,767	3,426
(iv) Bank balances other than (iii) above	2,827	61
(v) Loans	565	753
(vi) Other financial assets	1,989	1,372
(c) Contract assets	1,189	1,013
(d) Other current assets	1,978	1,780
Total current assets	**32,448**	**28,504**
Total assets	**1,57,832**	**1,49,144**
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	719	719
(b) Other equity	1,06,381	98,913
Total equity	**1,07,100**	**99,632**
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	15,281	16,250
(ii) Lease liabilities	12,919	13,257
(iii) Other financial liabilities	50	18
(b) Deferred tax liabilities (net)	3,375	3,560
(c) Other non-current liabilities	-	12
Total non-current liabilities	**31,625**	**33,097**
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	1,964	1,972
(ii) Lease liabilities	615	416
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises; and	731	968
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	10,903	8,589
(iv) Other financial liabilities	2,353	1,598
(b) Other current liabilities	1,763	1,785
(c) Provisions	778	1,087
Total current liabilities	**19,107**	**16,415**
Total liabilities	**50,732**	**49,512**
Total equity and liabilities	**1,57,832**	**1,49,144**

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Annexure-II

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of Standalone Cash Flows

(Rs. in Million)

PARTICULARS	For the period ended September 30, 2026	For the period ended September 30, 2025
A. Cash flow from Operating Activities		
Profit for the period	**8,607**	**7,268**
Adjustments for:		
Depreciation and amortisation expenses	2,753	2,456
Income Tax expense	2,617	2,235
(Profit)/loss on sale of property plant & equipment	29	(31)
Profit on sale of investments (net)	(79)	(81)
Gain on fair valuation of mutual funds	(261)	(525)
Gain on fair valuation of equity investments	(4)	(1)
Finance costs	1,395	1,167
Interest from banks/others	(460)	(428)
Dividend on non-current equity investments	(718)	(900)
Expected credit loss on trade receivables	305	222
Unrealised foreign exchange (gain)/loss (net)	(3)	9
Provision written back	(4)	-
Share based payment expense	312	-
Operating Profit before working capital changes	**14,489**	**11,391**
Adjustments for (increase)/decrease in operating assets		
Inventories	(258)	(67)
Trade receivables	(2,324)	(1,441)
Other financial assets	(457)	(173)
Other assets	(210)	316
	(3,249)	**(1,365)**
Adjustments for increase/(decrease) in operating liabilities		
Trade payables	2,080	855
Other financial liabilities	698	353
Provisions	(375)	89
Other liabilities	(33)	166
	2,370	**1,463**
Cash generated from operations	**13,610**	**11,489**
Net income tax paid	(2,495)	(2,051)
Net cash generated from operating activities (A)	**11,115**	**9,438**
B. Cash flow from investing Activities		
Purchase of Property, plant and equipment, capital work-in-progress and intangibles	(6,655)	(3,422)
Proceeds from sale of property, plant and equipment	11	98
Loans given	(1,671)	(1,022)
Repayments received towards loans	849	8
Purchase of non-current investments	(30)	(444)
Purchase of current investments	(8,051)	(9,508)
Proceeds from sale of current investments	9,649	5,644
Proceeds from/(Investment in) bank deposits	(2,727)	108
Interest received	141	104
Dividend received from subsidiaries and associates	718	900
Net cash used in investing activities (B)	**(7,766)**	**(7,534)**
C. Cash flow from financing activities		
Proceeds from borrowings	-	1,044
Payments towards lease liability	(819)	(577)
Repayment of borrowings	(977)	(930)
Finance costs	(774)	(777)
Dividends paid	(1,438)	(1,438)
Net cash used in financing activities (C)	**(4,008)**	**(2,678)**
Net Increase/(decrease) in cash and cash equivalents (A+B+C) = (D)	(659)	(774)
Cash and cash equivalents at the beginning of the period (E)	**3,426**	**2,332**
Cash and cash equivalents at the end of the period (D) +(E)	**2,767**	**1,558**
Cash and cash equivalents comprises of		
- Cash on hand	73	64
- Balance with banks	2,694	1,494
Total cash and cash equivalents at the end of the period	2,767	1,558

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

NOTES TO THE STANDALONE UNAUDITED FINANCIAL RESULTS:

1. The standalone unaudited financial results ("the statement") of **Apollo Hospitals Enterprise Limited** ("the Company") for the three and six months ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 3, 2026 and November 4, 2026 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the financial results for the three and six months ended September 30, 2026.

2. The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

3. The Company's business activity primarily falls within a single reportable business segment namely "Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind AS 108- "Segment Reporting".

4. The Board at its meeting held on June 30, 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL") – Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230–232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

   The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited and admission to trading.

   National Stock Exchange of India Limited and Bombay Stock Exchange Limited have issued letters dated December 23,2025 and December 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Based on the directions of the Hon'ble Company Law Tribunal, meetings of the Secured Creditors, Unsecured Creditors and the Equity Shareholders of the Company were convened on June 24, 2026 with requisite approvals being obtained for implementation of the Scheme and status being updated to the Company Law Tribunal. Subsequent to the receipt of such approvals, the Company has filed a petition before the National Company Law Tribunal seeking sanction of the scheme.

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited
Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

5. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.

6. The The Board of Directors in their meeting held on May 20, 2026, approved the proposal for merger of Apollo Hospitals North Limited, a wholly owned subsidiary with the Company.

7. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post-employment.

   The Company has assessed the financial implications of these changes, which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 114 million for the year ended March 31, 2026. Considering the materiality and regulatory driven non-recurring nature of this impact, the Company has presented the same as Exceptional item in the Statement, The Company continues to monitor the finalisation Of Central and State Rules, as well as Government clarifications on other aspects of the Labour Codes, and will incorporate appropriate accounting treatment based on these developments as required.

8. The standalone balance sheet as at September 30, 2026 and the statement of Cash flows for the six months ended September 30, 2026 are provided as annexure to this statement.

9. The aforesaid unaudited financial results are also available on the Company's website (www.apollohospitals.com).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai
Date: November 4, 2026

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Deloitte
Haskins & Sells LLP

Chartered Accountants
ASV Ramana Tower
52, Venkatnarayana Road
T. Nagar
Chennai-600 017
Tamil Nadu, India

Tel: +91 44 6688 5000

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
Apollo Hospitals Enterprise Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Apollo Hospitals Enterprise Limited** ("the Company"), for the three months and six months ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

DELOITTE HASKINS & SELLS LLP ★ CHENNAI-17 ★ CHARTERED ACCOUNTANTS

Nachiappan Subramanian
Partner
Membership No. 218727
UDIN: 26218727KWSWEA5267

Place: Chennai
Date: November 4, 2026

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of unaudited consolidated financial results for the three months and six months ended September 30, 2026

(Rs. in Million)

Particulars	Three months ended 30/09/2026	Preceding three months ended 30/06/2026	Corresponding three months ended 30/09/2025	Year to date figures for current period ended 30/09/2026	Year to date figures for previous period ended 30/09/2025	Previous year ended 31/03/2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Continuing Operations						
1 **Income**						
(a) Revenue from operations	76,149	69,319	61,888	1,45,468	1,19,236	2,47,737
(b) Other income	448	479	545	927	943	1,870
Total Income (a + b)	**76,597**	**69,798**	**62,433**	**1,46,395**	**1,20,179**	**2,49,607**
2 **Expenses**						
(a) Cost of materials consumed	9,352	8,150	7,659	17,502	14,920	29,889
(b) Purchases of stock-in-trade	30,590	27,678	24,647	58,268	47,802	1,00,564
(c) Changes in inventories of stock-in-trade	(426)	3	2	(423)	(78)	(216)
(d) Employee benefits expense	8,732	7,770	7,490	16,502	14,446	29,286
(e) Finance costs	1,140	1,081	986	2,221	1,958	3,996
(f) Depreciation and amortisation expense	2,302	2,224	2,053	4,526	4,072	8,260
(g) Other expenses	15,993	14,948	12,846	30,941	24,557	51,368
Total expenses	**67,683**	**61,854**	**55,683**	**1,29,537**	**1,07,677**	**2,23,147**
3 **Profit before share of profit/(loss) in associates / joint ventures and exceptional items (1) - (2)**	**8,914**	**7,944**	**6,750**	**16,858**	**12,502**	**26,460**
4 Share of profit/(loss) of associates /joint ventures	119	134	63	253	199	449
5 **Profit before tax and exceptional items from continuing operations (3) + (4)**	**9,033**	**8,078**	**6,813**	**17,111**	**12,701**	**26,909**
6 Exceptional item (Refer note 6)	-	-	-	-		(192)
7 **Profit before tax from continuing operations (5) + (6)**	**9,033**	**8,078**	**6,813**	**17,111**	**12,701**	**26,717**
8 **Tax expenses**						
Current tax	2,542	2,103	1,615	4,645	2,863	6,279
Deferred tax	(93)	(219)	192	(312)	361	289
9 **Profit after tax for the period/year from continuing operations (7) - (8)**	**6,584**	**6,194**	**5,006**	**12,778**	**9,477**	**20,149**
Discontinued Operations (Refer Note 8)						
a) Profit/(loss) before tax for the period/year from discontinued operations	49	(90)	(66)	(41)	(127)	(108)
b) Tax expenses/(benefit) of discontinued operations	38	-	-	38	-	14
10 **Profit after tax for the period/year from discontinued operations**	**11**	**(90)**	**(66)**	**(79)**	**(127)**	**(122)**
11 **Profit after tax for the period/year (9) + (10)**	**6,595**	**6,104**	**4,940**	**12,699**	**9,350**	**20,027**
12 **Other Comprehensive Income**						
Items that will not be reclassified to profit or loss						
Remeasurement gains / (losses) on defined benefit plan	(109)	40	(92)	(69)	(31)	(116)
Equity instruments through other comprehensive income	-	-	745	-	745	735
Income tax relating to items that will not be reclassified to profit or loss	19	(2)	(96)	17	(98)	(64)
Items that will be reclassified to profit or loss	-	-				
Exchange differences in translating the financial statements of foreign operations	4	1	11	5	11	29
Total other comprehensive income/ (loss)	**(86)**	**39**	**568**	**(47)**	**627**	**584**
13 **Total comprehensive income for the period/year (11) + (12)**	**6,509**	**6,143**	**5,508**	**12,652**	**9,977**	**20,611**
Profit for the period/ year attributable to:						
Owners of the parent	6,299	5,807	4,772	12,106	9,100	19,417
Non-controlling interest	296	297	168	593	250	610
Other comprehensive income/ (loss) for the period/ year attributable to:						
Owners of the parent	(87)	40	565	(47)	625	577
Non-controlling interest	1	(1)	3	0	2	7
Total comprehensive income for the period/ year attributable to:						
Owners of the parent	6,212	5,847	5,337	12,059	9,725	19,994
Non-controlling interest	297	296	171	593	252	617
14 Paid-up equity share capital (Face value Rs.5/- per share)				719	719	719
Reserves (excluding revaluation reserves)				1,05,245	90,136	94,004
15 **Earnings per equity share ('EPS') of Rs.5/- each**						
From continuing operations						
Basic EPS for the period/year (Rs.)	*43.74	*41.01	*33.51	*84.74	*63.90	135.63
Diluted EPS for the period/year (Rs.)	*43.71	*41.00	*33.51	*84.69	*63.90	135.53
From discontinued operations						
Basic EPS for the period/year (Rs.)	*0.08	*(0.63)	*(0.31)	*(0.55)	*(0.61)	*(0.59)
Diluted EPS for the period/year (Rs.)	*0.08	*(0.63)	*(0.31)	*(0.55)	*(0.61)	*(0.59)

*Not annualised

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Annexure I

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Consolidated balance sheet

(Rs. in Million)

Particulars	As at September 30, 2026	As at March 31, 2026
	Unaudited	Audited
ASSETS		
Non-current assets		
(a) Property, plant and equipment	84,068	82,586
(b) Right Of use assets	25,964	27,800
(c) Capital work-in-progress	14,939	9,915
(d) Investment property	19	22
(e) Goodwill	10,300	10,323
(f) Other intangible assets	1,675	1,985
(g) Intangible assets under development	433	409
(h) Investments accounted for using the equity method	2,739	2,564
(i) Financial assets		
(i) Investments	9,075	9,058
(ii) Loans	23	156
(iii) Other financial assets	2,544	3,530
(j) Deferred tax assets (net)	138	141
(k) Income tax assets (net)	1,442	1,961
(l) Other non-current assets	3,182	2,521
Total non-current assets	**1,56,541**	**1,52,971**
Current assets		
(a) Inventories	6,234	5,424
(b) Financial assets		
(i) Investments	10,103	10,165
(ii) Trade receivables	42,562	34,849
(iii) Cash and cash equivalents	5,874	8,113
(iv) Bank balances other than (iii) above	7,834	3,055
(v) Loans	106	24
(vi) Other financial assets	1,767	2,086
(c) Contract assets	2,076	1,862
(d) Other current assets	3,819	3,420
Assets held for sale	5,306	-
Total current assets	**85,681**	**68,998**
Total assets	**2,42,222**	**2,21,969**
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	719	719
(b) Other equity	1,05,323	94,082
Equity attributable to owners of the Company	**1,06,042**	**94,801**
Non-controlling interests	5,529	4,944
Total equity	**1,11,571**	**99,745**
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	24,487	24,301
(ii) Lease liabilities	23,994	26,703
(iii) Other financial liabilities	341	300
(b) Provisions	760	995
(c) Deferred tax liabilities (net)	4,685	4,982
(d) Other non-current liabilities	133	130
Total non-current Liabilities	**54,400**	**57,411**
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	31,461	32,284
(ii) Lease liabilities	1,551	1,641
(iii) Trade payables		
(a) Total outstanding dues to micro enterprises and small enterprises; and	1,080	1,226
(b) Total outstanding dues to creditors other than micro enterprises and small enterprises	26,497	21,292
(iv) Other financial liabilities	3,800	3,310
(b) Other current liabilities	3,068	3,081
(c) Provisions	1,736	1,953
(d) Current tax liabilities (net)	9	26
Liabilities directly associated with assets classified as held for sale	7,049	-
Total current liabilities	**76,251**	**64,813**
Total liabilities	**1,30,651**	**1,22,224**
Total equity and liabilities	**2,42,222**	**2,21,969**

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Annexure II

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Consolidated Segment wise revenue, results, segment assets and segment liabilities

(Rs. in Million)

Particulars	Three months ended 30/09/2026	Preceding three months ended 30/06/2026	Corresponding three months ended 30/09/2025	Year to date figures for current period ended 30/09/2026	Year to date figures for previous period ended 30/09/2025	Previous year ended 31/03/2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.Segment revenue						
a) Healthcare services	39,630	36,101	32,136	75,731	61,804	1,27,238
b) Retail health and diagnostics	4,293	3,879	3,592	8,172	6,870	14,104
c) Digital health and pharmacy distribution	32,858	29,770	26,605	62,628	51,324	1,08,081
d) Others	64	107	50	171	133	316
SUB - TOTAL	**76,845**	**69,857**	**62,383**	**1,46,702**	**1,20,131**	**2,49,739**
Less : Intersegmental revenue	696	538	495	1,234	895	2,002
Revenue from operations	**76,149**	**69,319**	**61,888**	**1,45,468**	**1,19,236**	**2,47,737**
2. Segment results						
a) Healthcare services	7,600	6,844	6,319	14,444	11,956	24,364
b) Retail health & diagnostics	380	211	108	591	143	416
c) Digital health & pharmacy distribution	1,728	1,523	859	3,251	1,551	3,987
d) Others	(102)	(32)	(95)	(134)	(133)	(181)
SUB - TOTAL	**9,606**	**8,546**	**7,191**	**18,152**	**13,517**	**28,586**
Less: (i) Finance cost	(1,140)	(1,081)	(986)	(2,221)	(1,958)	(3,996)
Add: (ii) Other un-allocable income, (net of expenditure)	448	479	545	927	943	1,870
Add: (iii) Share of profit/(loss) of associates / joint ventures	119	134	63	253	199	449
Less: (iv) Exceptional item (Refer note 6)	-	-	-	-	-	(192)
3. Profit before tax from continuing operations	**9,033**	**8,078**	**6,813**	**17,111**	**12,701**	**26,717**
4. Profit before tax from discontinued operations (Refer Note 8)	**49**	**(90)**	**(66)**	**(41)**	**(127)**	**(108)**
5. Profit before tax - (3) + (4)	**9,082**	**7,988**	**6,747**	**17,070**	**12,574**	**26,609**
a) Healthcare services						
Segment assets	1,77,544	1,71,434	1,62,276	1,77,544	1,62,276	1,63,075
Segment liabilities	(62,697)	(60,457)	(58,046)	(62,697)	(58,046)	(57,348)
b) Retail health and diagnostics						
Segment assets	11,579	16,201	15,698	11,579	15,698	15,959
Segment liabilities	(14,948)	(21,545)	(21,294)	(14,948)	(21,294)	(21,383)
c) Retail health and diagnostics-Discontinued operations (Refer Note 8)						
Segment assets	5,306			5,306		
Segment liabilities	(7,049)			(7,049)		
d) Digital health and pharmacy distribution						
Segment assets	46,241	42,972	40,277	46,241	40,277	41,493
Segment liabilities	(44,035)	(42,168)	(43,152)	(44,035)	(43,152)	(41,805)
e) Others						
Segment assets	1,552	1,504	1,249	1,552	1,249	1,442
Segment liabilities	(1,921)	(1,778)	(1,474)	(1,921)	(1,474)	(1,689)
Total	**1,11,571**	**1,06,162**	**95,534**	**1,11,571**	**95,534**	**99,745**

"The Company has allocated the entire assets and liabilities on a reasonable basis to its existing segments in line with the revised method used by the company to present segment information to its chief operating decision makers. Consequently, the Company has also re-presented the previously reported unallocated segment assets and liabilities to the existing segments in line with the revised method of allocation."

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Annexure III

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of consolidated cash flows

(Rs. in Million)

Particulars	For the period ended September 30, 2026	For the period ended September 30, 2025
A. Cash flow from Operating Activities		
Profit for the period from continuing operations	**12,778**	**9,477**
Profit for the period from discontinued operations	**(79)**	**(127)**
Adjustments for:		
Depreciation and amortisation expense	4,526	4,325
(Profit)/loss on sale of property, plant & equipment	43	(14)
Profit on sale of investments (net)	(85)	(82)
Share of (profit)/loss of associates	(253)	(199)
Income tax expense	4,371	3,223
Finance costs	2,221	2,179
Interest income	(313)	(426)
Dividend income	(2)	(17)
Expected credit loss on trade receivables	576	507
Provision written back	(68)	(1)
Gain on fair valuation of mutual funds	(293)	(525)
Gain on fair valuation of existing interest of a joint venture pursuant to acquisition of control	-	(11)
Loss /(gain) on fair valuation of equity investments	(3)	36
Share-based compensation expense	616	593
Gain on termination of lease	(183)	-
Operating cash flow before working capital changes	**23,852**	**18,938**
(Increase)/decrease in operating assets		
Inventories	(849)	(241)
Trade receivables	(8,571)	(4,943)
Other financial assets	(598)	(85)
Other assets	(891)	273
Contract assets	(214)	(65)
	(11,123)	**(5,061)**
Increase/(decrease) in operating liabilities		
Trade payables	6,011	801
Other financial liabilities	809	900
Provisions	(372)	187
Other liabilities	82	245
	6,530	**2,133**
Cash generated from operations	**19,259**	**16,010**
Net income tax paid	(4,326)	(2,757)
A. Net cash generated from operating activities (A)	**14,933**	**13,253**
B. Cash flow from Investing Activities		
Purchase of Property, plant and equipment, capital work-in-progress and intangibles	(11,999)	(7,065)
Proceeds from sale of property, plant and equipment	43	107
Proceeds from /(Investment) in bank deposits	(3,014)	67
Purchase of investments in subsidiaries	(3)	(174)
Purchase of non current investments	(28)	(11)
Purchase of current investments	(9,195)	(9,495)
Proceeds from sale of current investments	9,649	5,644
Loans given	-	(333)
Repayments received towards loans	51	254
Interest received	275	290
Dividend Received	83	17
B. Net cash used in investing activities (B)	**(14,138)**	**(10,699)**
C. Cash flow from financing activities		
Proceeds from issue of equity instruments by a subsidiary company	63	13
Proceeds from borrowings	2,409	1,382
Repayment of borrowings	(1,213)	(746)
Finance costs	(1,175)	(1,305)
Dividend paid on equity shares	(1,438)	(1,438)
Dividend paid by subsidiary to Non Controlling Interest	(66)	(52)
Payment towards lease liability	(1,530)	(1,338)
C. Net cash used in financing activities (C)	**(2,950)**	**(3,484)**
Net increase in cash and cash equivalents (A+B+C) = (D)	**(2,155)**	**(930)**
Cash and cash equivalents at the beginning of the period (E)	8,113	5,781
Add:Cash balance in aquired entity	-	33
Less: Cash and cash equivalents reclassified as held-for-sale	(84)	-
Cash and cash equivalents at the end of the period (D) +(E)	5,874	4,884
Cash and cash equivalents comprises of		
- Cash on hand	121	125
- Balance with banks	5,753	4,759
Total cash and cash equivalents at the end of the period	5,874	4,884

Net cashflows attributable to discontinued operations are as follows:

Particulars	For the period ended September 30, 2026	For the period ended September 30, 2025
Net cash generated from operating activities	419	90
Net cash generated/(used) in investing activities	(9)	(154)
Net cash generated/(used) in financing activities	(412)	30

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

NOTES TO THE STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS:

1. The consolidated unaudited financial results ("the statement") of **Apollo Hospitals Enterprise Limited** ("the Company") for the three and six months ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 3, 2026 and November 4, 2026 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three and six months ended September 30, 2026.

2. The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

3. The Board at its meeting held on June 30, 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL") – Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230–232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

   The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited and admission to trading.

   National Stock Exchange of India Limited and Bombay Stock Exchange Limited have issued letters dated December 23, 2025 and December 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Based on the directions of the Hon'ble Company Law Tribunal, meetings of the Secured Creditors, Unsecured Creditors and the Equity Shareholders of the Company were convened on June 24, 2026 with requisite approvals being obtained for implementation of the Scheme and status being updated to the Company Law Tribunal . Subsequent to the receipt of such approvals, the Company has filed a petition before the National Company Law Tribunal seeking sanction of the scheme.

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

4. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.

5. The Board of Directors in their meeting held on May 20, 2026, approved the proposal for merger of Apollo Hospitals North Limited, a wholly owned subsidiary with the Company.

6. On November 21, 2025, the Government of India notified provisions or the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post-employment.

   The Group has assessed the financial implications of these changes, which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs 192 million for the year ended March 31,2026. Considering the materiality and regulatory- driven non-recurring nature of this impact, the Group has presented the same as Exceptional Items in the statement. The Group continues to monitor the finalisation of Central and State Rules, as well as Government clarifications on other aspects of the Labour Codes, and will incorporate appropriate accounting treatment based on these developments as required.

7. The Honourable High Court of Karnataka on October 8, 2021 had set aside the order of the Revenue Department, State of Karnataka ("Revenue Department") initiated earlier against a subsidiary alleging non-compliance with certain conditions associated with the allotment of land to the subsidiary and had directed the Revenue Department to reconsider and dispose the matter. The Revenue Department had issued a show cause notice dated February 9, 2022 seeking explanations as to why the original order should be withdrawn, for which the subsidiary had filed a detailed response explaining that there were no violations of the conditions relating to the allotment of land.

   During the previous year ended March 31, 2026, the Revenue Department passed an order dated February 13, 2026 cancelling the grant order, alleging that the land had been alienated by the subsidiary on account of share purchase by its holding company. The subsidiary has challenged the said order before the Honourable High Court of Karnataka. The Honourable High Court of Karnataka has granted an interim stay on April 10, 2026 against the cancellation order and has directed the Revenue Department to file its objections.

   Based on external legal opinions received, including opinions supporting that transfer of shares does not constitute transfer, alienation or sub-lease of immovable property owned by the subsidiary, the group believes that it has adequate grounds to demonstrate compliance with the applicable conditions of the land grant. Accordingly, the subsidiary has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in its favour.

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

8. The Apollo Health and Lifestyle Limited ("AHLL"), a wholly owned subsidiary of the Company, had planned to divest its stake in its subsidiaries, namely Apollo Specialty Hospitals Private Limited ("ASPL") and Apollo Fertility Centre Private Limited ("AFCPL"), to Kids Clinic India Limited. The transaction has been approved by the Board of Directors of the Company at its meeting held on May 20, 2026 and received the approval from the Competition Commission of India (CCI) on September 1, 2026. Further on October 12, 2026, AHLL completed the divestment of the aforesaid subsidiaries. Accordingly, under Ind-AS 105, the Company had identified the assets and liabilities relating to ASPL and AFCPL as disposal group and classified the respective business as discontinued operations. The assets and liabilities relating to the discontinued operations have been disclosed as asset held for sale and liabilities relating to assets held for sale as of September 30, 2026.

   The results of discontinued operations are as below:

Particulars	Three months ended 30/09/2026	Preceding three months ended 30/06/2026	Corresponding three months ended 30/09/2025	Year to date figures for period ended 30/09/2026	Year to date figures for period ended 30/09/2025	Previous year ended 31/03/2026
Total income	1,426	1,125	1,150	2,551	2,227	4,595
Total expenses	1,377	1,215	1,216	2,592	2,354	4,703
Profit/(Loss) before tax	49	(90)	(66)	(41)	(127)	(108)
Tax expenses	(38)	-	-	(38)	-	(14)
Profit/ Loss after tax	11	(90)	(66)	(79)	(127)	(122)

   Consequent to the discontinued operations, the amounts presented in the comparative periods in the statement of consolidated unaudited financial results have been represented to conform to the current period classification.

9. The consolidated balance sheet as at September 30, 2026 and the statement of consolidated cash flows for the six months period ended September 30, 2026 are provided as annexure to this statement

10. The aforesaid unaudited financial results are also available on the Company's website (www.apollohospitals.com).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai
Date: November 4, 2026

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Deloitte
Haskins & Sells LLP

Chartered Accountants
ASV Ramana Tower
52, Venkatnarayana Road
T. Nagar
Chennai-600 017
Tamil Nadu, India

Tel: +91 44 6688 5000

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
Apollo Hospitals Enterprise Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Apollo Hospitals Enterprise Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income (net) of its associates and joint ventures for the three months and six months ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relationship
Apollo Hospitals Enterprise Limited (AHEL)	Parent
Apollo Home Healthcare Limited (AHHL)	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary

DELOITTE HASKINS & SELLS LLP CHENNAI-17 CHARTERED ACCOUNTANTS

Deloitte
Haskins & Sells LLP

Name of the Company	Relationship
Imperial Hospitals & Research Centre Limited (IHRCL)	Subsidiary
Belenus Champion Hospitals Limited (w.e.f 2 February 2026)	Subsidiary of IHRCL
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Care Diagnostics Private Limited (w.e.f.1 February 2026)	Subsidiary of AHLL
Apollo Dialysis Philippines Inc.	Subsidiary of AHLL
Apollo Fertility Centre Private Limited (Formerly known as Surya Fertility Centre Private Limited)	Stepdown Subsidiary of AHLL
Apollo Spectra Centres Private Limited (Formerly known as Kshema Healthcare Private Limited)	Stepdown Subsidiary of AHLL
Apollo Cradle and Children Hospital Private Limited	Stepdown Subsidiary of AHLL
Apollo Nellore Hospital Limited	Subsidiary
Sapien Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo CVHF Limited	Subsidiary of AHIL
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital Private Limited (ARHPL)	Subsidiary
Sobhagya Hospital and Research Centre Private Limited	Subsidiary of ARHPL
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited (Assam)	Subsidiary
Asclepius Hospitals and Healthcare Private Limited	Subsidiary of Assam
Apollomedics International Lifesciences Limited	Subsidiary
Apollo Multi Specialty Hospitals Limited (AMSHL)	Subsidiary
Apollo HealthCo Limited (AHL)	Subsidiary
Apollo 24/7 Insurance Services Limited	Subsidiary of AHL
Apollo Consumer Products Limited (w.e.f 31 March 2026)	Subsidiary of AHL
Apollo Medical Private Limited (AMPL)	Associate of AHL
Apollo Pharmacies Limited	Subsidiary of AMPL
Apollo Pharmalogistics Private Limited	Subsidiary of AMPL
Apollo Pharma Products Pvt Limited	Subsidiary of AMPL
Apollo Hospitals North Limited	Subsidiary
Kerala First Health Services Private Limited (KFHS)	Subsidiary



Name of the Company	Relationship
Baalayam Healthcare Private Limited	Subsidiary of KFHS
Health Axis Private Limited (HAPL)	Subsidiary
Apollo Health Axis Inc (w.e.f 12 November 2025)	Subsidiary of HAPL
Opstronomy Health Technologies Private Limited (w.e.f. 17 June 2026)	Subsidiary of HAPL
Nexify Health Private Limited	Joint venture of HAPL
Apollo Hospitals Jammu and Kashmir Limited	Subsidiary
Apollo Hospitals Worli LLP	Subsidiary
Apollo Healthtech Limited (w.e.f. 10 June 2025)	Subsidiary
Apollo Gleneagles PET-CT Private Limited (w.e.f 30 September 2025)	Subsidiary
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate
ApoKos Rehab Private Limited	Joint venture

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We draw attention to Note 7 to the Statement in respect of proceedings initiated against the subsidiary, Imperial Hospitals & Research Centre Limited, by the Government of Karnataka. Our conclusion on the Statement is not modified in respect of this matter.

7. We did not review the interim financial results/financial information of 28 subsidiaries included in the consolidated unaudited financial results, whose interim financial results/financial information reflect total assets of Rs. 44,753 million as at September 30, 2026 and, total revenues of Rs. 6,306 million and Rs. 11,982 million for the three months and six months ended September 30, 2026 respectively, total net profit after tax of Rs. 193 million and Rs. 648 million for the three months and six months ended September 30, 2026 respectively and total comprehensive income (net) of Rs. 197 million and Rs. 651 million for the three and six months ended September 30, 2026 respectively and net cash outflows of Rs. 1,394 million for the six months ended September 30, 2026, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of net profit after tax of Rs. 124 million and Rs. 254 million for the three months and six months ended September 30, 2026 respectively and total comprehensive income (net) of Rs. 122 million and Rs. 257 million for the three months and



six months ended September 30, 2026 respectively, as considered in the Statement, in respect of 1 joint ventures and 5 associates (including 3 subsidiaries of 1 associate), whose interim financial results/financial information have not been reviewed by us. These interim financial results/financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

8. The consolidated unaudited financial results includes the interim financial results/financial information of 9 subsidiaries which have not been reviewed by their auditors, whose interim financial results/financial information reflect total assets of Rs. 720 million as at September 30, 2026 and, total revenue of Rs. 60 million and Rs. 106 million for the three months and six months ended September 30, 2026 respectively, total net profit after tax of Rs. 17 million and Rs. 28 million for the three months and six months ended September 30, 2026 respectively and total comprehensive income (net) of Rs. 15 million and Rs. 25 million for the three months and six months ended September 30, 2026 respectively and net cash outflows of Rs. 16 million for the six months ended September 30, 2026, as considered in the Statement. The consolidated unaudited financial information also includes the Group's share of loss after tax of Rs. 12 million and Rs. 13 million for the three months and six months ended September 30, 2026 respectively and total comprehensive loss of Rs. 12 million and Rs. 13 million for the three months and six months ended September 30, 2026 respectively, as considered in the Statement, in respect of 2 associates, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial results/financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial results/financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Nachiappan Subramanian
Partner
Membership No. 218727
UDIN: 26218727OYFHXM3648

Place: Chennai
Date: November 4, 2026

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

Annexure – B

Sl.No	Particulars	Details
1	Name of the Senior Management Personnel	Dr. Madhu Sasidhar
2	Reason for change	Cessation from the position of President & CEO – Hospitals Division consequent to the successful completion of his employment tenure
3	Date of Cessation	With effect from the closure of business hours on November 14, 2026
4	Brief profile (in case of appointment)	Not Applicable
5	Disclosure of relationships between directors	Not Applicable

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohosp
Website : www.apollohospitals.com

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

Annexure - C

s.no	Particulars	Details	Details	Details
1	Name of the Senior Management Personnel	**Dr. Ritu Garg,** Chief Executive Officer, Multi Region (North, Central, Western and Eastern)	**Mr. Anand Wasker** Chief Business Officer, International	**Dr. N. Venkatesan** Chief Procurement Officer
2	Reason for change	Designated as Senior Management Personnel	Designated as Senior Management Personnel	Designated as Senior Management Personnel
3	Date of Appointment	Designated as Senior Management Personnel with effect from 4th November 2026	Designated as Senior Management Personnel with effect from 4th November 2026	Designated as Senior Management Personnel with effect from 4th November 2026
4	Brief profile (in case of appointment)	Dr. Ritu Garg has a extensive and diverse work experience in the healthcare industry having held leadership roles in companies such as Fortis Healthcare, Fortis Memorial Research Institute, and Fortis Lafemme Limited. She has been Chief Growth & Innovation Officer, Zonal Director and Board Member. In addition, she has also been involved in starting and co-founding initiatives such as Doctopinion.com and Healdaddy.com. Dr Ritu has also worked as a Principal Consultant at Amrop India, where she focused on healthcare and	Anand has over 26 years of leadership experience building, scaling and transforming large service businesses across healthcare, financial services, telecom, education, beauty and wellness consumer services. He holds a Masters in Business Management from Neville Wadia Institute of Management Studies & Research, University of Pune. In his most recent role as President, Global Services at VLCC Ltd., he was responsible for strategy & innovation, revenue & profitability,	Dr. Venkatesan holds a Ph.D. in Hospital Supply Chain Management and an MBA in Systems and brings over 25 years of diverse experience across healthcare procurement, supply chain, pharmacy operations, materials management, commercial functions, and hospital project execution. Prior to joining Apollo, he was with Max Healthcare Institute Ltd., New Delhi, where he served as Director & Chief Procurement Officer from August 2021. In this role, he led the group's procurement and supply chain functions across pharmacy, medical and

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohosp
Website : www.apollohospitals.com

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

		life sciences. Dr. Garg has expertise in strategy development, medical programs, clinical talent management, and medical alliances. She has demonstrated a strong ability to drive growth and innovation, develop business plans, and improve business performance. Dr. Ritu Garg completed her education with an MBA in Finance and Strategy from the Indian School of Business in 2009. Prior to that, she pursued a degree in M.B.B.S and M.S in ENT from Delhi University	operations & customer service, marketing & strategic alliances, network expansion, people development & compliance across India, Middle East & South Asia.	non-medical consumables, medical and non-medical equipment, service contracts, and upcoming hospital projects. His responsibilities included strategic sourcing, cost optimisation, vendor negotiations, procurement planning, budgeting for new hospital construction, due diligence for acquisitions, MIS and P&L reviews, and setting up pharmacy, stores, and purchase functions for new hospitals.
5.	Disclosure of relationships between directors	Not applicable	Not applicable	Not applicable

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohosp
Website : www.apollohospitals.com

November 4, 2026

Apollo Hospitals Q2FY27 Results

Q2 FY27 Consolidated Revenue grew 23% YoY to Rs. 7,615 Crore

Q2 FY27 Consolidated EBITDA grew 29% YoY to Rs. 1,191 Crore

Q2 FY27 Consolidated PAT grew 32% YoY to Rs. 630 Crore

H1 FY27 Consolidated Revenue grew 22% YoY to Rs. 14,547 Crore

H1 FY27 Consolidated EBITDA grew 29% YoY to Rs. 2,268 Crore

H1 FY27 Consolidated PAT grew 33% YoY to Rs. 1,211 Crore

- **Q2 FY27 Healthcare Services revenue at Rs. 3,900 Crore, grew 23% YoY; EBITDA at Rs. 937 crore.**
- **Q2 FY27 Apollo Health and Lifestyle Limited revenue at Rs. 429 Crore, grew 20% YoY; EBITDA at Rs. 61 crore.**
- **Q2 FY27 Apollo HealthCo reported revenue of Rs. 3,286 Crore and EBITDA of Rs. 193 Crore.**
- Apollo Hospital's expansion programme is on track to add ~ 5,800 beds over the next five years.
- Gurugram facility with ~470 beds remain on track for commissioning in Q3 FY27.
- Revenue growth driven by Robust volume increase in Congo Specialties and high Complexity Clinical work aided by key specialties like Oncology (28% growth), Gastro (27%), Cardiac and Ortho (20%) and Urology (26%).
- International Patient Services revenue grew 37% YoY in Q2 FY27, reinforcing Apollo's position as a preferred global healthcare destination.
- Apollo continues to ramp up operations at its newly commissioned hospitals in :
  - Swargate – Pune ~ 400 beds (Phase 1 &2)
  - Financial District – Hyderabad ~ 400 beds
  - Defence colony – Delhi ~ 30 beds
  - Sonarpur - Kolkata ~ 265 beds
  - Sarjapur – Bengaluru ~ 185 beds

  Of this 1280 total beds and 1000 Operating / Census beds, 520 operating beds have now been commissioned, and the balance will be commissioned over the next 12 months.

KEY CLINICAL HIGHLIGHTS

During Q2 FY27, Apollo Hospitals continued to advance its clinical capabilities, achieving significant milestones in robotic surgery, transplantation, specialised care and technology-enabled healthcare.

1. **Robotic Surgery:** Apollo Hospitals, Greams Road, Chennai, crossed 2,000 cumulative robotic-assisted orthopaedic surgeries across knee and hip replacements.

2. **Transplant Excellence:** Apollo Hospitals, Greams Road, Chennai, successfully performed bilateral lung transplantation in a 41-year-old woman with end-stage lung disease after 119 consecutive days on VV-ECMO, using a single oxygenator without circuit exchange throughout the bridge to transplantation.

3. **Technology-enabled Emergency Care:** Apollo Hospitals, Visakhapatnam, inaugurated an advanced Command Centre connecting hospital specialists with smart ambulances, tele-ECG services across more than 15 peripheral nursing homes and telemedicine capabilities, strengthening emergency and cardiac care delivery.

4. **Advanced Gastrointestinal Care:** Apollo Hospitals, Narendrapur, Kolkata, successfully performed its first Per-Oral Endoscopic Myotomy (POEM) procedure for achalasia cardia, expanding access to advanced minimally invasive treatment.

5. **Advanced Stroke Care:** Apollo Hospitals, Jayanagar, performed mechanical thrombectomy in a 72-year-old man with Gerstmann syndrome and an MRI-negative acute ischaemic stroke after identifying a middle cerebral artery cortical branch occlusion. Successful recanalisation resulted in complete reversal of neurological deficits.

6. **Regenerative Urology:** Apollo Medics Hospitals, Lucknow, performed endoscopic implantation of tissue-engineered autologous buccal mucosal cells for a long-segment urethral stricture, offering a minimally invasive regenerative alternative to open surgery.

Dr. Prathap C. Reddy, Founder & Chairman, Apollo Hospitals Group, said:

"The performance in this Quarter was supported by the revenue growth driven by robust volume increase in Congo T Specialties. I am encouraged by the progress we are making across our businesses and the contribution each one of our hospitals are making to the Group.

India's healthcare needs are changing. People are living longer, medical conditions are becoming more complex, and the need for specialised care is growing. We must prepare for these needs well in advance. This means investing not only in hospitals and technology, but also in doctors, nurses and allied health professionals. Equally important is the ability to identify illness earlier and ensure that patients receive continuous care. Ultimately, the strength of a healthcare institution is measured by the quality of care it provides and the trust it earns from patients and their families.

We are in an important phase of investment for Apollo. We must continue to build on the strength of our established businesses while developing the hospitals, clinical programmes and services that will serve patients in the years ahead.

Our expansion programme, which includes plans to add ~ 5,800 beds over the next five years, is guided by this long-term responsibility. We are progressing with the ramp-up of our hospitals at Financial District, Hyderabad; Sonarpur, Kolkata; and Sarjapur, Bengaluru, which was commissioned in Q1 FY27. Our Gurugram facility remains on track for commissioning in Q3 FY27. Building a hospital is only the beginning. What matters is the strength of its clinical teams, the range and quality of specialised services it can provide, and the confidence it builds among the people it serves. Our focus is on ensuring that each of these hospitals develops into a dependable centre of care for its community.

During Q2, we also took forward our Always Open, Always Here initiative, extending routine and planned services to Sundays, subject to local schedules and service readiness. For many working people and families, finding time for a consultation or health check is not always easy. We must recognise these practical barriers and make it simpler for people to seek care. Preventive healthcare begins with making access easier. Alongside our diagnostics, pharmacies and digital platforms, this initiative gives us more opportunities to reach people earlier and support them through their healthcare journey.

As we enter H2 FY27, our attention is on execution: improving operating performance, supporting the development of our newer hospitals and maintaining discipline in the way we allocate capital. I have always believed that India's healthcare sector has enormous potential but realising it requires institutions to think long term and invest responsibly. When I founded Apollo, my belief was that the people of India deserved access to the finest medical care. Over the years, we have built the experience, people and capabilities to take that vision further. Our responsibility now is to ensure that this progress translates into timely, compassionate and dependable care for more families."

Q2FY27 FINANCIAL PERFORMANCE

Consolidated Q2 FY27 Performance

- Revenue at Rs. 7,615 crore vs Rs. 6,189 crore in Q2 FY26; growth of 23% YoY
- EBITDA at Rs. 1,191 crore vs Rs. 924 crore in Q2 FY26; growth of 29% YoY; margin at 16%
- EBITDA includes Apollo 24/7 costs of Rs. 91 crore during the quarter, including a non-cash ESOP charge of Rs. 14 crore, compared with costs of Rs. 126 crore, including a non-cash ESOP charge of Rs. 32 crore in Q2 FY26
- Reported PAT at Rs. 630 crore vs Rs. 477 crore in Q2 FY26; growth of 32% YoY
- Diluted EPS from Continuing Operations of Rs. 43.71 per share in Q2 FY27, not annualized

Healthcare Services Q2 FY27 Performance

- Revenue at Rs. 3,900 crore vs Rs. 3,169 crore in Q2 FY26; growth of 23% YoY
- EBITDA at Rs. 937 crore vs Rs. 780 crore in Q2 FY26; growth of 20% YoY; margin at 24%
- PAT at Rs. 486 crore vs Rs. 408 crore in Q2 FY26; growth of 19% YoY

Apollo Health and Lifestyle Limited Q2 FY27 Performance

- Revenue at Rs. 429 crore vs Rs. 359 crore in Q2 FY26; growth of 20% YoY
- EBITDA at Rs. 61 crore vs Rs. 34 crore in Q2 FY26; margin at 14%
- PAT at Rs. 26 crore vs PAT loss of Rs. 4 crore in Q2 FY26
- ***Note:*** *AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly. Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations.*

Apollo HealthCo Q2 FY27 Performance

- Revenue at Rs. 3,286 crore vs Rs. 2,661 crore in Q2 FY26; growth of 23% YoY
- EBITDA at Rs. 193 crore vs Rs. 110 crore in Q2 FY26; margin at 6%
- PAT at Rs. 118 crore vs Rs. 73 crore in Q2 FY26

Q2 FY27 Operating Highlights

- Hospital occupancy at 73% in Q2 FY27, compared with 69% in Q2 FY26
- Healthcare Services IP volumes grew by 14% YoY; ARPP stood at Rs. 1,86,880 an increase of 8% YoY
- 222 net new pharmacy stores added during Q2 FY27
- Platform GMV grew 20%, while Core Segment GMV grew (27% YoY Growth): Rs 571 Crore in Q2 FY27, over Rs. 450 Crore in Q2 FY26 (excluding GST impact)

H1FY27 FINANCIAL PERFORMANCE

Consolidated H1 FY27 Performance

- Revenue at Rs. 14,547 crore vs Rs. 11,924 crore in H1 FY26; growth of 22% YoY
- EBITDA at Rs. 2,268 crore vs Rs. 1,759 crore in H1 FY26; growth of 29% YoY; margin at 16%
- Apollo 24/7 costs at Rs. 182 crore, including a non-cash ESOP charge of Rs. 24 crore, compared with costs of Rs. 247 crore, including a non-cash ESOP charge of Rs. 57 crore, in H1 FY26
- Reported PAT at Rs. 1,211 crore vs Rs. 910 crore in H1 FY26; growth of 33% YoY
- Diluted EPS from Continuing Operations of Rs. 84.69 per share in H1 FY27, not annualized

Healthcare Services H1 FY27 Performance

- Revenue at Rs. 7,467 crore vs Rs. 6,104 crore in H1 FY26; growth of 22% YoY
- EBITDA at Rs. 1,798 crore vs Rs. 1,497 crore in H1 FY26; growth of 20% YoY; margin at 24%
- PAT at Rs. 965 crore vs Rs. 791 crore in H1 FY26; growth of 22% YoY

Apollo Health and Lifestyle Limited H1 FY27 Performance

- Revenue at Rs. 817 crore vs Rs. 687 crore in H1 FY26; growth of 19% YoY
- EBITDA at Rs. 106 crore vs Rs. 58 crore in H1 FY26; margin at 13%
- PAT at Rs. 26 crore vs PAT loss of Rs. 10 crore in H1 FY26
- ***Note:*** *AHLL completed the transfer of its stake in ASPL and AFCPL to Kids Clinic India Limited on October 12, 2026. In accordance with Ind AS 105, these businesses have been classified as discontinued operations and comparative-period financials have been re-presented accordingly. Financials up to EBIT have been re-presented, while PBT and PAT include discontinued operations.*

Apollo HealthCo H1 FY27 Performance

- Revenue at Rs. 6,263 crore vs Rs. 5,132 crore in H1 FY26; growth of 22% YoY
- EBITDA at Rs. 364 crore vs Rs. 204 crore in H1 FY26; margin at 6%
- PAT at Rs. 220 crore vs Rs. 130 crore in H1 FY26

H1 FY27 Operating Highlights

- Hospital occupancy at 71% in H1 FY27, compared with 67% in H1 FY26
- Healthcare Services IP volumes grew by 14% YoY; ARPP stood at Rs. 1,86,760 an increase of 8% YoY
- 373 net new pharmacy stores added during H1 FY27
- Platform GMV grew 18% while Core segment GMV grew (24% YoY Growth): Rs 1,072 Crore in H1 FY27, over Rs. 867 Crore in H1 FY26 (excluding GST impact)

SEGMENT WISE PERFORMANCE UPDATE

Healthcare Services Hospitals

As at September 30, 2026, Apollo Hospitals had 8,522 operating beds across the network, excluding AHLL and managed beds. Overall occupancy during Q2 FY27 stood at 73%, compared with 69% in Q2 FY26.

Consolidated revenue from the Healthcare Services division increased by 23% to Rs. 3,900 crore in Q2 FY27, compared with Rs. 3,169 crore in Q2 FY26. EBITDA, post Ind AS 116, stood at Rs. 937 crore in Q2 FY27, compared with Rs. 780 crore in Q2 FY26, representing growth of 20% YoY.

New hospitals Revenue is at Rs.135 crore in Q2FY27 and EBITDA loss of 35 crore in Q2FY27.

Regional performance

Tamil Nadu: Revenue grew by 19% YoY, IP volumes grew by 14% YoY, and ARPP grew by 6% YoY to Rs. 2,17,162. Average occupied beds stood at 1,436, representing occupancy of 72%, compared with 1,306 beds and occupancy of 63% in Q2 FY26.

AP–Telangana: Revenue grew by 30% YoY, IP volumes grew by 22% YoY, and ARPP grew by 7% YoY to Rs. 1,98,406. Average occupied beds stood at 1,021, representing occupancy of 71%, compared with 874 beds and occupancy of 68% in Q2 FY26.

Karnataka: Revenue grew by 26% YoY, IP volumes grew by 16% YoY, and ARPP grew by 11% YoY to Rs. 1,94,937. Average occupied beds stood at 614, representing occupancy of 70%, compared with 547 beds and occupancy of 70% in Q2 FY26.

Eastern: Revenue grew by 17% YoY, IP volumes grew by 12% YoY, and ARPP grew by 6% YoY to Rs. 1,56,749. Average occupied beds stood at 1,527, representing occupancy of 77%, compared with 1,429 beds and occupancy of 79% in Q2 FY26.

Western: Revenue grew by 31% YoY, IP volumes grew by 19% YoY, and ARPP grew by 11% YoY to Rs. 1,72,284. Average occupied beds stood at 651, representing occupancy of 67%, compared with 534 beds and occupancy of 60% in Q2 FY26.

Northern: Revenue grew by 16% YoY, IP volumes grew by 6% YoY, and ARPP grew by 10% YoY to Rs. 1,77,965. Average occupied beds stood at 950, representing occupancy of 77%, compared with 866 beds and occupancy of 72% in Q2 FY26.

Apollo Health and Lifestyle Limited AHLL

- AHLL gross revenue at Rs. 429 crore; 20% YoY growth
- Diagnostics revenue at Rs. 227 crore; 24% YoY growth; Spectra revenue at Rs. 84 crore; 15% YoY growth.
- EBITDA at Rs. 61 crore; margin at 14%
- ***Note**: The Apollo Health and Lifestyle Limited ("AHLL"), a wholly owned subsidiary of the Company, had planned to divest its stake in its subsidiaries, namely Apollo Specialty Hospitals Private Limited ("ASPL") and Apollo Fertility Centre Private Limited ("AFCPL"), to Kids Clinic India Limited. The transaction has been approved by the Board of Directors of the Company at its meeting held on May 20, 2026 and received the approval from the Competition Commission of India (CCI) on September 1, 2026. Further on October 12, 2026, AHLL completed the divestment of the aforesaid subsidiaries. Accordingly, under Ind-AS 105, the Company had identified the assets and liabilities relating to ASPL and AFCPL as disposal group and classified the respective business as discontinued operations. The assets and liabilities relating to the discontinued operations have been disclosed as asset held for sale and liabilities relating to assets held for sale as of September 30, 2026. Consequent to the discontinued operations, the amounts presented in the comparative periods in the statement of consolidated unaudited financial results have been represented to conform to the current period classification.*

Apollo HealthCo

- Offline pharmacy distribution revenue at Rs. 2,885 crore in Q2 FY27; revenue from the digital platform at Rs. 401 crore. Overall HealthCo revenue at Rs. 3,286 crore; 23% YoY growth. 222 net new stores opened during the quarter, taking the total network to 7,662 stores as at September 30, 2026.
- GMV of Apollo 24/7 at Rs. 615 crore in Q2 FY27; growth of 20% YoY. Average Q2 FY27 order rate of 77K per day across pharmacy, diagnostics and consultations compared with 67K per day in Q2 FY2

EXPANSION INNOVATION AND PARTNERSHIPS

During Q2 FY27, Apollo continued to advance its healthcare expansion, technology and innovation agenda through capacity creation, new models of patient access and strategic collaborations.

1. **Capacity Expansion:** Apollo continued to ramp up operations at its Financial District hospital in Hyderabad, Sonarpur hospital in Kolkata and Sarjapur hospital in Bengaluru, with its Gurugram facility on track for commissioning in Q3 FY27. The Group's broader expansion programme envisages adding over 5,800 beds over the next five years, strengthening its presence across key markets.

2. **Always Open, Always Here:** Launched on August 18, 2026, the Group-wide initiative extends routine and planned healthcare services to Sundays, including outpatient consultations, diagnostics, preventive health checks, follow-ups and scheduled procedures, improving access and convenience for patients.

3. **Advancing Critical Care:** Apollo Hospitals and Medtronic inaugurated an 11-bed ICU of the Future at Apollo Hospitals, Jubilee Hills, Hyderabad, on July 16, 2026. The facility integrates advanced acute-care monitoring technologies with clinical expertise, creating an environment for technology-enabled critical care and clinical innovation.

4. **Research and Workforce Development**: Apollo Knowledge and BITS Pilani signed an MoU on September 29, 2026, to collaborate on healthcare research, education and workforce development through joint research initiatives and work-integrated learning programmes for healthcare professionals and managers.

AWARDS AND ACCOLADES

Apollo Hospitals was honored with the ET Family Business Award in the Large Business category in July 2026, recognising its enduring legacy and contribution to India's healthcare sector.

Apollo Hospitals and its network continued to earn recognition for clinical excellence, patient care, technology and quality during the year. Key recognitions included:

1. **ET Healthcare Awards 2026:** Multiple national and regional honours for Apollo ProHealth (Health & Wellness Technology), Apollo Spectra Hospitals (Laparoscopic and Short-stay Surgery), Indraprastha Apollo Hospitals, Delhi (Green Hospital), Apollo Adlux Hospital, Kochi (Critical Care) and Apollomedics, Lucknow (Critical Care). Individual honours included recognition for Dr. Rakesh Jalali (Visionary Leadership) and Dr. Jyoti Bajpai (Oncology).

2. **The Week–HANSA Best Hospitals Awards 2025**: Recognitions for Apollo Hospitals, Ahmedabad (Ranked No. 2), Indraprastha Apollo Hospitals, Delhi, Apollo Health City, Hyderabad, Apollo Multispeciality Hospitals, Kolkata and Apollomedics, Lucknow.

3. **AHPI Excellence in Healthcare Awards 2026:** Recognitions for Apollo Hospitals, Ahmedabad and Guwahati for Nursing Excellence and Digital Excellence, and Apollo Adlux Hospital, Kochi, for Excellence in Operations and Emergency Services.

4. **Clinical Excellence and Medical Education**: Apollo Hospitals, Bannerghatta Road and Jayanagar, Bengaluru, were recognised as ISAKOS-approved teaching centres for Orthopaedics and Sports Medicine. Apollo Hospitals, Vizag, received multiple Financial Express Healthcare Summit honours across Cardiac Care, Emergency & Critical Care, Oncology and Orthopaedics.

5. **Healthcare Innovation and Technology:** Apollo Hospitals, Ahmedabad, received recognition for robotic surgery at Building Bharat: The Gujarat Chapter 2026, while Apollo Sage Hospitals, Bhopal, received two honours at the CII Western Region Health Innovation Awards 2026.

6. **Other Quality and Sustainability Recognitions**: Indraprastha Apollo Hospitals, Delhi, received an Honourable Mention at the IHF Awards 2025 for Healthcare Workers' Wellbeing. Apollo Hospitals, Navi Mumbai, was recognised for Sustainable Healthcare Practices, while Apollo Specialty Hospitals, Trichy, secured NABH 6th Edition Accreditation.

CORPORATE SOCIAL RESPONSIBILITY

During Q2 FY27, Apollo Foundation continued to advance its community healthcare and development initiatives. Apollo Foundation – Total Health reached 2.13 lakh direct beneficiaries through AHEL CSR-funded programmes, with interventions spanning mental wellbeing, healthcare services, clean drinking water and sanitation. The Foundation also expanded rural healthcare access through the inauguration of three Connected Mobile Medical Units in Meghalaya and continued its Rural Integrated Community Development Project across 10 villages in East Khasi Hills.

Billion Hearts Beating Foundation reached over 2.2 lakh beneficiaries through community healthcare, senior citizen care and emergency preparedness initiatives. Community Care programmes reached over 1.8 lakh people through health camps, medicine distribution, awareness and counselling sessions, and emergency care services. Senior Citizen Care supported 17,244 beneficiaries through monthly medicines, geriatric health camps, physiotherapy, yoga and essential healthcare amenities. Additionally, 22,283 people received Basic Life Support (BLS) and First Aid training, strengthening community-level emergency preparedness.

About Apollo

Apollo revolutionised healthcare when Dr. Prathap Reddy opened its first hospital in Chennai in 1983. Today, Apollo is the world's largest integrated healthcare platform. As of Sep 30, 2026, its network comprised 65 hospitals with a capacity of 10,733 census beds, 7,662 pharmacy stores, 290 primary care clinics and 2,922 diagnostic centres. Apollo continues to invest in research and innovation, introducing advanced technologies, equipment and treatment protocols to give patients access to world-class care. Apollo's 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it.

***For further details, log onto**: www.apollohospitals.com*

For Media / Investors

R Krishnakumar
Apollo Hospitals Enterprise Ltd.
Krishnakumar_r@apollohospitals.com
+91 44 2829 7840

Mayank Vaswani
CDR India
mayank@cdr-india.com
+91 22 6645 1230

Disclaimer:

Some of the statements in this document that are not historical facts are forward looking statements. These forward-looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate.

These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward-looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly-competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry.

Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings.